Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IntReALL HR 2010 for high-risk first relapse acute lymphoblastic leukemia in children
MOH_2018-03-13_002112Phase 2Not yet recruiting
- Sponsor
- ד"ר רונית אלחסיד
- Start
- Apr 2016
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bortezomib in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by ד"ר רונית אלחסיד. Planned start Apr 2016; status: not yet recruiting.
02
Drugs
bortezomib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on MOH_2018-03-13_002112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-03-13_002112.